3 research outputs found
ACTG A5175/Pearls trial β Survival probability estimate from randomization to treatment failure by pill count non-adherence (solid line β=β did not miss any pills; dashed line β=β missed any pills).
<p>ACTG A5175/Pearls trial β Survival probability estimate from randomization to treatment failure by pill count non-adherence (solid line β=β did not miss any pills; dashed line β=β missed any pills).</p
Risk Factors of Time to Treatment Failure.
1<p>All adjusted models include treatment condition.</p><p>Table Legend:</p><p>QOL_health: general health perceptions.</p><p>QOL_mental: mental health.</p
Baseline Participant Characteristics.
<p>Table Legend:</p><p>QOL_health: general health perceptions.</p><p>QOL_mental: mental health.</p><p>Treatment: Once daily protease inhibitor + nucleoside reverse transcriptase inhibitors: atazanavir + didanosine-EC and emtricitabine.</p><p>Treatment: Once daily non-nucleoside reverse transcriptase inhibitor + nucleoside reverse transcriptase inhibitors: efavirenz + co-formulated emtricitabine-tenofovir-DF.</p><p>Standard of care: efavirenz plus co-formulated lamivudine-zidovudine.</p